ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 075,68
0,99%
Dow Jones
38 879,08
0,07%
DAX
18 430,05
1,42%
Brent Oil
83,265
-0,25%
Bitcoin
63 322,30
0,25%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. G1 Therapeutics Inc (GTHX)

  7. G1 Therapeutics Inc (GTHX) Actualités

GTHX G1 Therapeutics Inc

4,215
-0,055 (-1,29%)
Dernière mise à jour : 19:42:46
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
G1 Therapeutics Inc GTHX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,055 -1,29% 4,215 19:42:46
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,27 4,1201 4,28 4,27
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202423:50GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
01/5/202412:30GLOBEG1 Therapeutics Provides First Quarter 2024 Financial..
01/5/202412:25GLOBEG1 Therapeutics and Pepper Bio Announce Global (Excluding..
17/4/202415:00GLOBEG1 Therapeutics to Release First Quarter 2024 Financial..
04/4/202416:30GLOBEG1 Therapeutics to Participate in the 23rd Annual Needham..
01/4/202422:20GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
01/3/202422:20GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
28/2/202412:35EDGAR2Form 8-K - Current report
28/2/202412:30GLOBEG1 Therapeutics Provides Fourth Quarter and Full Year 2023..
27/2/202414:30GLOBEG1 Therapeutics to Participate in the TD Cowen 44th Annual..
15/2/202414:30GLOBEG1 Therapeutics to Release Fourth Quarter and Full Year 2023..
14/2/202400:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:42EDGAR2Form 144 - Report of proposed sale of securities
12/2/202422:19EDGAR2Form 8-K - Current report
12/2/202422:05GLOBEG1 Therapeutics to Continue Pivotal Phase 3 Trial of..
09/1/202422:19EDGAR2Form 144 - Report of proposed sale of securities
08/1/202412:45GLOBEG1 Therapeutics Provides Corporate Update at the 42nd Annual..
08/1/202412:30EDGAR2Form 8-K - Current report
08/1/202412:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202412:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202412:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202412:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202412:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202412:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:00GLOBEG1 Therapeutics to Participate in the 42nd Annual J.P...
03/1/202401:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202422:51GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
13/12/202322:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202322:40EDGAR2Form 144 - Report of proposed sale of securities
12/12/202300:43EDGAR2Form 144 - Report of proposed sale of securities
05/12/202315:26GLOBEG1 Therapeutics Presents New Post Hoc Analyses Indicating..
01/12/202322:27GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
30/11/202302:37GLOBEG1 Therapeutics Announces Upcoming Presentation at the 2023..
01/11/202321:37EDGAR2Form S-8 - Securities to be offered to employees in employee..
01/11/202321:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202311:46EDGAR2Form 8-K - Current report
01/11/202311:30GLOBEG1 Therapeutics Provides Third Quarter 2023 Financial..
27/10/202313:00GLOBEReal World Data Indicate That Trilaciclib Reduces..
18/10/202314:00GLOBEG1 Therapeutics’ COSELA® (trilaciclib) Recommended in..
18/10/202313:30GLOBEG1 Therapeutics to Release Third Quarter 2023 Financial..
16/10/202315:00GLOBEG1 Therapeutics Announces Upcoming Presentations at the 2023..
21/9/202322:15EDGAR2Form 8-K - Current report
18/9/202313:00GLOBEBlack Diamond Therapeutics Announces CEO Transition
05/9/202317:00GLOBEG1 Therapeutics to Participate in the H.C. Wainwright 25th..
01/9/202322:15GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
10/8/202322:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202301:28EDGAR2Form 144 - Report of proposed sale of securities
02/8/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/8/202312:50EDGAR2Form 8-K - Current report
02/8/202312:30GLOBEG1 Therapeutics Provides Second Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
GTHX
G1 Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés